A 32-year-old woman presents to the clinic with a 6-month history of progressive exertiona… — USMLE Step 2 CK

A 32-year-old woman presents to the clinic with a 6-month history of progressive exertional dyspnea, fatigue, and occasional exertional syncope. Physical examination reveals a right ventricular heave, a loud pulmonic component of the second heart sound (P2), and clear lung fields. A transthoracic echocardiogram demonstrates right atrial and ventricular enlargement with an estimated right ventricular systolic pressure of $65 \text{ mm Hg}$ . Left ventricular size and function are normal, with no left-sided valvular abnormalities. Arrange the following diagnostic and therapeutic steps in the most appropriate sequential order for the standard evaluation and definitive management of this patient's condition.

1Perform a radionuclide ventilation/perfusion (V/Q) scan to evaluate for chronic thromboembolic disease.
2Perform right heart catheterization to definitively measure pulmonary arterial pressure and pulmonary capillary wedge pressure.
3Administer inhaled nitric oxide during catheterization to assess for acute pulmonary vasoreactivity.
4Initiate definitive treatment with a high-dose calcium channel blocker if the hemodynamic profile demonstrates a significant drop in pulmonary pressure.
5Transition to targeted therapies such as an endothelin receptor antagonist or phosphodiesterase-5 inhibitor if clinical deterioration occurs over time.

Answer

The correct sequence for evaluating and managing unexplained pulmonary hypertension is: 1) V/Q scan, 2) Right heart catheterization, 3) Vasoreactivity testing, 4) Calcium channel blocker trial (if reactive), and 5) Escalation to advanced PAH therapies if efficacy wanes.

The evaluation of pulmonary hypertension follows a rigorous, stepwise algorithm. Following echocardiographic suspicion, the first mandatory step is a V/Q scan to rule out chronic thromboembolic pulmonary hypertension (CTEPH), which is potentially curable surgically. Once CTEPH and left-heart/lung diseases are excluded, a right heart catheterization (RHC) is performed to definitively diagnose pre-capillary pulmonary arterial hypertension (PAH). During the RHC, acute vasoreactivity testing is essential. Patients who demonstrate a reactive hemodynamic profile are initiated on high-dose calcium channel blockers. If a patient initially responds to CCBs but later deteriorates, or if they are non-reactive from the start, therapy is escalated to targeted PAH agents such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors.

Step-by-Step Solution

Rule out Group 4 Pulmonary Hypertension (CTEPH)

Perform a V/Q scan to look for mismatched perfusion defects.

CTEPH is uniquely treatable with pulmonary thromboendarterectomy. It must be evaluated prior to invasive hemodynamics or medical therapy.

Confirm diagnosis hemodynamically

Perform right heart catheterization (RHC).

Echocardiography only estimates pressures. RHC is required to confirm pre-capillary pulmonary hypertension (

\text{mPAP} > 20 \text{ mm Hg}

\text{PCWP} \leq 15 \text{ mm Hg}

\text{PVR} \geq 2 \text{ WU}

Determine phenotype for medical therapy

Administer a short-acting vasodilator (e.g., inhaled nitric oxide) during the RHC.

Vasoreactivity testing identifies the minority of patients with idiopathic PAH who will respond favorably to calcium channel blockers.

Initiate first-line therapy for reactive patients

Start high-dose calcium channel blockers (CCBs).

Reactive patients have an excellent prognosis on CCBs and should be treated with them initially.

Manage treatment failure or disease progression

Escalate to targeted PAH therapies (e.g., ERAs, PDE-5 inhibitors, or prostacyclin analogs).

Patients who lose reactivity or clinically deteriorate on CCBs require advanced, pathway-specific pulmonary vasodilators.

Key Concept

The diagnostic algorithm for suspected pulmonary arterial hypertension requires non-invasive screening for CTEPH via a V/Q scan, followed by definitive hemodynamic confirmation via right heart catheterization with concurrent vasoreactivity testing to guide targeted pharmacotherapy.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic